Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review
Authors' conclusion
Licensed ready-to-administer products are associated with fewer preparation errors, shorter preparation times and reduced drug waste, with plausible economic benefits.
Study context
- Population
- Hospital settings using IV medications16 studies
- Comparison
- Licensed ready-to-administer IV products vs standard vials and ampoules
- Outcome
- Cost, waste, preparation time, medication errors
Pooled result
As reported in the abstract
- Ready-to-administer products generally reduced preparation errors, drug wastage and preparation time; meta-analysis precluded by variability in outcome measures
- Fewer adverse drug events and workflow interruptions, mainly from observational studies and surrogate outcomes
- Economic evaluations indicated potential savings from avoided errors, reduced waste and staff time; estimates context-specific and assumption-dependent
- Risk of bias varied; mainly small, single-centre, non-randomised designs
Original publication
Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review. Anaesthesia. Published 14 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →